Neurocrine Biosciences, Inc.

Summary

Profile

Financials

Events

Ownership

Options

Company Info

Industry	Biotechnology
Sector	Health Technology
Employees	845
CEO	Dr. Kevin Charles Gorman

Address	12780 El Camino Real , San Diego, CA 92130
Phone	1.858.617.7600
Website	www.neurocrine.com

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders. The firm's product includes INGREZZA. The company was founded by Kevin C. Gorman and Wylie W. Vale in January 1992 and is headquartered in San Diego, CA.

Competitors

Company Name	3 Month %Change	1 Year %Change
Neurocrine Biosciences, Inc.	11.47%	4.72%
Hill-Rom Holdings, Inc.	31.81%	68.36%
Zai Lab Ltd.	-40.07%	15.48%
Penumbra, Inc.	6.79%	24.30%
Ascendis Pharma A/S	30.32%	1.58%

Statement Summary

as of 4:00 ET PM 10/14/2021

Total Assets (MRQ)	2.0 B
Total Liabilities (MRQ)	677.2 M
Shareholders’ Equity (MRQ)	1.3 B
Total Revenue (Annual)	288.9 M
Net Income (Annual)	42.3 M

Earnings And Estimates

as of 4:00 ET PM 10/14/2021

Current Qtr EPS Estimate	0.60
Current FY EPS Estimate	2.25
Long Term EPS Growth Estimate	17.25
Next Expected Earnings Date	//

NBIX vs S&P 500

as of 10/14/2021

	Relative To S&P 500	NBIX
4 Weeks	n/a	n/a
12 Weeks	n/a	n/a
YTD	n/a	n/a

Earnings Surprises

as of 4:00 ET PM 10/14/2021

Fiscal Quarter	Estimate	Actual	Surprise
06/2021	0.50	0.43	-14.33%
03/2021	0.53	0.33	-37.45%
12/2020	0.60	3.58	+495.25%
09/2020	-0.02	-0.62	+3,093.90%
06/2020	0.66	0.81	+22.50%
03/2020	0.52	0.39	-25.17%
12/2019	0.78	0.35	-54.93%
09/2019	0.66	0.56	-15.65%

Financial Strength

as of 4:00 ET PM 10/14/2021

Pre-Tax Margin	19.90
Net Margin	-44.38
Operating Margin	23.47
Return On Equity	34.56
Return On Assets	21.01
Inventory Turnover (TTM)	0.84
Sales Growth (MRQ)	121.16

Ratios

as of 4:00 PM ET 10/14/2021

Price/Earnings (TTM)	27.58
Price/Book (MRQ)	7.73
Price/Cash Flow (TTM)	39.00
Book Value (MRQ)	13.52
Quick Ratio (MRQ)	5.08
Current Ratio (MRQ)	5.21
Total Debt/Equity (MRQ)	0.35

Short Interest

as of 4:00 PM ET 10/15/2021

	% Short - 0.00%
	% Remaining Float - 100.00%

	Current	Last Month
Short Interest Date	n/a	n/a
Short Interest Shares	0	0
Short Interest Ratio	0.0	0.0

M Y M Y

Total Assets 0,0.00 0,0.00

Total Liabilities 0,0.00 0,0.00

Total Equity 0,0.00 0,0.00

M Y M Y

Total Revenue 0,0.00 0,0.00

EBT Exc.
Unusual Items 0,0.00 0,0.00

Net Income 0,0.00 0,0.00

M Y M Y

Cash from
Operations 0,0.00 0,0.00

Cash from
Activities 0,0.00 0,0.00

Cash from
Fin. Activities 0,0.00 0,0.00

Select Period

TOTAL ASSETS	TOTAL LIABILITIES	TOTAL EQUITY

Balance Sheet

	M Y
ASSETS
Cash And Equivalents	0,0.00
Receivables	0,0.00
Inventories	0,0.00
Other Current Assets	0,0.00
Total Current Assets	0,0.00
Property, Plant & Equipment, Gross	0,0.00
Accumulated Depreciation & Depletion	0,0.00
Property, Plant & Equipment, Net	0,0.00
Intangibles	0,0.00
Other Non-Current Assets	0,0.00
Total Non-Current Assets	0,0.00
TOTAL ASSETS	0,0.00
Liabilities & Shareholder Equity
Accounts Payable	0,0.00
Short Term Debt	0,0.00
Total Current Liabilities	0,0.00
Long Term Debt	0,0.00
Deferred Income Taxes	0,0.00
Other Non-Current Liabilities	0,0.00
Minority Interest	0,0.00
Total Non-Current Liabilities	0,0.00
Preferred Stock Equity	0,0.00
Common Stock Equity	0,0.00
Common Par	0,0.00
Additional Paid In Capital	0,0.00
Cumulative Translation Adjustment	0,0.00
Retained Earnings	0,0.00
Treasury Stock	0,0.00
Other Equity Adjustments	0,0.00
Total Capitalization	0,0.00
TOTAL EQUITY	0,0.00
TOTAL LIABILITIES & STOCK EQUITY	0,0.00
Total Common Shares Outstanding	0,0.00
Preferred Shares	0,0.00
Treasury Shares	0,0.00
Basic Weighted Shares Outstanding	0,0.00
Diluted Weighted Shares Outstanding	0,0.00
Number Of Employees	0,0.00
Number Of Part-Time Employees	0,0.00

Select Period

TOTAL REVENUES	EBT Excluding Unusual Items	NET INCOME

Income Statement

	M Y
Sales	0,0.00
Cost Of Sales	0,0.00
Gross Operating Profit	0,0.00
Selling, General, And Administrative Expenses	0,0.00
Research & Development	0,0.00
Operating Income Before D & A (EBITDA)	0,0.00
Depreciation & Amortization	0,0.00
Interest Income	0,0.00
Other Income - Net	0,0.00
Special Income / Charges	0,0.00
Total Income Before Interest Expenses (EBIT)	0,0.00
Interest Expense	0,0.00
Pre-Tax Income	0,0.00
Income Taxes	0,0.00
Minority Interest	0,0.00
Net Income From Continuing Operations	0,0.00
Net Income From Discontinued Operations	0,0.00
Net Income From Total Operations	0,0.00
Extraordinary Income/Losses	0,0.00
Income From Cum. Effect Of Acct. Change	0,0.00
Income From Tax Loss Carryforward	0,0.00
Other Gains / Losses	0,0.00
Total Net Income	0,0.00
Normalized Income (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Preferred Dividends	0,0.00
Net Income Available To Common	0,0.00
Basic EPS From Continuing Ops.	0,0.00
Basic EPS From Discontinued Ops.	0,0.00
Basic EPS From Total Operations	0,0.00
Basic EPS From Extraordinary Inc.	0,0.00
Basic EPS From Cum Effect Of Accounting Change	0,0.00
Basic EPS From Tax Loss Carryf'd.	0,0.00
Basic EPS From Other Gains (Losses)	0,0.00
Basic EPS, Total	0,0.00
Basic Normalized Net Income/Share	0,0.00
EPS From Continuing Ops.	0,0.00
EPS From Discontinued Ops	0,0.00
EPS From Total Ops.	0,0.00
EPS From Extraord. Inc.	0,0.00
EPS From Cum Effect of Accounting Change	0,0.00
EPS From Tax Loss Carfd.	0,0.00
EPS From Other Gains (L)	0,0.00
EPS, Total	0,0.00
Diluted Normalized Net Inc/Shr (Net Income From Continuing Operations, Ex. Special Income / Charge)	0,0.00
Dividends Paid Per Share	0,0.00

Select Period

CASH FROM OPERATIONS	CASH FROM INVESTING ACTIVITIES	CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

	M Y
Cash Flow From Operating Activities
Net Income (Loss)	0,0.00
Operating Gains/Losses	0,0.00
Gross Operating Profit	0,0.00
(Increase) Decrease In Receivables	0,0.00
(Increase) Decrease In Inventories	0,0.00
(Increase) Decrease In Other Current Assets	0,0.00
(Decrease) Increase In Other Current Liabilities	0,0.00
(Increase) Decrease In Other Working Capital	0,0.00
Other Non-Cash Items	0,0.00
Net Cash From Continuing Operations	0,0.00
Net Cash From Discontinued Operations	0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities	0,0.00
Sale Of Property, Plant & Equipment	0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments	0,0.00
Purchases Of Property, Plant & Equipment	0,0.00
Acquisitions	0,0.00
Purchases Of Short-Term Investments	0,0.00
Other Cash From Investing Activities	0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities	0,0.00
Issuance Of Debt	0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock	0,0.00
Repayment Of Long-Term Debt	0,0.00
Repurchase Of Capital Stock	0,0.00
Payment Of Cash Dividends	0,0.00
Other Financing Charges, Net	0,0.00
Net Cash From Financing Activities	0,0.00
Effect Of Exchange Rate Changes	0,0.00
Net Change In Cash & Cash Equivalents	0,0.00

Earnings Estimates

as of 4:00 ET PM 10/14/2021

	Current Qtr (09/2021)	Next Qtr (12/2021)
Consensus Estimate	$0.60	$0.72
# of Estimates	21	21
High Estimate	$1.06	$1.23
Low Estimate	$0.06	$0.11
Year Ago EPS	$-0.62	$3.72
Year Over Year Growth Estimate	-197.41%	-80.55%

	Current Yr (12/2021)	Next Yr (12/2022)
Consensus Estimate	$2.25	$3.71
# of Estimates	23	23
High Estimate	$3.90	$6.62
Low Estimate	$0.93	$0.33
Year Ago EPS	$4.16	$2.25
Year Over Year Growth Estimate	-45.99%	65.15%

	Current Qtr (09/2021)	Next Qtr (12/2021)	Current Year (12/2021)	Next Year (12/2022)
Consensus Estimate	$0.60	$0.72	$2.25	$3.71
# of Estimates	21	21	23	23
High Estimate	$1.06	$1.23	$3.90	$6.62
Low Estimate	$0.06	$0.11	$0.93	$0.33
Year Ago EPS	$-0.62	$3.72	$4.16	$2.25
Year Over Year Growth Estimate	-197.41%	-80.55%	-45.99%	65.15%